Skripsi
NILAI MODIFIED GLASGOW PROGNOSTIC SCORE SEBAGAI PREDIKTOR MORTALITAS KANKER PARU STADIUM LANJUT DI RS MOHAMMAD HOESIN PALEMBANG
Background: Lung cancer is a malignant tumor originating from lung tissue, including the respiratory epithelium. It is one of the leading causes of cancer-related mortality worldwide and is frequently diagnosed at an advanced stage with a poor prognosis. Systemic inflammation and nutritional status play important roles in disease progression and patient survival. The modified Glasgow Prognostic Score (mGPS), which combines serum C-reactive protein (CRP) and albumin levels, is a simple parameter with potential prognostic value for mortality in patients with advanced-stage lung cancer. Methods: This study was a prognostic study. The study subjects were patients with advanced-stage lung cancer hospitalized at Mohammad Hoesin Hospital, Palembang, who met the inclusion and exclusion criteria. Collected data included demographic characteristics, CRP and albumin levels for mGPS assessment, and patient survival data. Statistical analyses were performed using SPSS version 25 to evaluate the association between mGPS and survival. Results: Most subjects were aged ≥60 years (54.1%), with a mean age of 59.81±9.89 years, and were predominantly male (75.7%). Multivariate analysis demonstrated that mGPS was an independent prognostic factor for survival. Patients with an mGPS score of 1 had a 2.68-fold higher risk of mortality compared to those with an mGPS score of 0 (adjusted hazard ratio [aHR] 2.68; 95% CI: 1.05–7.36; p = 0.046). The risk of mortality was further increased in patients with an mGPS score of 2, with a 3.57-fold higher risk compared to mGPS 0 (aHR 3.57; 95% CI: 1.12–13.22; p = 0.047). Conclusion: The modified Glasgow Prognostic Score is significantly associated with survival in patients with advanced-stage lung cancer. Higher mGPS values reflect a poorer prognosis, indicating that mGPS may serve as a simple, objective, and easily applicable prognostic indicator in clinical practice.